{"success":true,"data":{"pressRelease":{"id":"134313","rtpr_id":"nGNX3zKwzz","ticker":"AURA","exchange":"NASDAQ","all_tickers":["AURA"],"title":"Aura Biosciences to Participate in Upcoming Investor Conference","author":"Globe Newswire","published_at":"2026-09-02T20:01:00.190Z","article_body":"BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc.\n(https://www.globenewswire.com/Tracker?data=ObuhW8OAe4pHI98m2Wg_fRGVPpkeT1FwAEHM6gabUPJ1VPWqoLd31W69KJPTtq2Ebr8OA10V_HPvep1w5_U51IdnDgSEfIwrX-dJeFLjAxLmggoXCU1zxF1gC5DCWBYZ)\n(NASDAQ: AURA), a clinical-stage biotechnology company developing a\npotentially transformative first-in-class therapy for patients with ocular\ncancers, today announced that Natalie Holles, CEO and President, will\nparticipate in the following upcoming investor conference:\n* Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday,\nSeptember 16, 2026.\nFireside Chat at 2:35 p.m. ET\nThe live webcast of the fireside chat will be available on the “Investors &\nMedia” page under the “Events & Presentations” section of the\nCompany’s website\nat https://ir.aurabiosciences.com/events-and-presentations, where a replay of\nthe webcast will be archived for 90 days following the presentation date.\n\nAbout Aura Biosciences\n\nAura Biosciences is a clinical-stage biotechnology company developing bel-sar,\na potentially transformative, first-in-class therapy for patients living with\nocular cancers. Bel-sar represents an entirely novel approach to treating\nocular cancers via its dual mechanisms of action of acute tumor necrosis and\nsecondary anti-tumor immune activation. The Phase 3 registration study of\nbel-sar in early choroidal melanoma, the largest patient segment of uveal\nmelanoma, is fully enrolled, and earlier stage studies in metastases to the\nchoroid and cancers of the ocular surface are ongoing. Aura's mission is to\nimprove outcomes for patients living with ocular cancers by delivering a\ntherapy that not only arrests tumor growth but also preserves vision and\nquality of life.\n\nFor more information, visit aurabiosciences.com\n(https://www.globenewswire.com/Tracker?data=QjwCmJi5polviKtuuL5SXXs8dXhuoPpT_Goa5vcHq3MAKDHVd-M9xj6nFMvZJwHdmJGKDtgMRJoqgrQUTKxlfiCM3rnQsfc1HDWC5YehvJo=).\nFollow us on X, @AuraBiosciences, and visit us on LinkedIn.\n\nInvestor and Media Relations Contact:\n\nAlex Dasalla\n\nHead of Investor Relations and Corporate Communications\n\nIR@aurabiosciences.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3zKwzz","title":"Aura Biosciences to Participate in Upcoming Investor Conference","author":"Globe Newswire","ticker":"AURA","created":"2026-09-02T20:01:00.190Z","tickers":["AURA"],"exchange":"NASDAQ","article_body":"BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc.\n(https://www.globenewswire.com/Tracker?data=ObuhW8OAe4pHI98m2Wg_fRGVPpkeT1FwAEHM6gabUPJ1VPWqoLd31W69KJPTtq2Ebr8OA10V_HPvep1w5_U51IdnDgSEfIwrX-dJeFLjAxLmggoXCU1zxF1gC5DCWBYZ)\n(NASDAQ: AURA), a clinical-stage biotechnology company developing a\npotentially transformative first-in-class therapy for patients with ocular\ncancers, today announced that Natalie Holles, CEO and President, will\nparticipate in the following upcoming investor conference:\n* Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday,\nSeptember 16, 2026.\nFireside Chat at 2:35 p.m. ET\nThe live webcast of the fireside chat will be available on the “Investors &\nMedia” page under the “Events & Presentations” section of the\nCompany’s website\nat https://ir.aurabiosciences.com/events-and-presentations, where a replay of\nthe webcast will be archived for 90 days following the presentation date.\n\nAbout Aura Biosciences\n\nAura Biosciences is a clinical-stage biotechnology company developing bel-sar,\na potentially transformative, first-in-class therapy for patients living with\nocular cancers. Bel-sar represents an entirely novel approach to treating\nocular cancers via its dual mechanisms of action of acute tumor necrosis and\nsecondary anti-tumor immune activation. The Phase 3 registration study of\nbel-sar in early choroidal melanoma, the largest patient segment of uveal\nmelanoma, is fully enrolled, and earlier stage studies in metastases to the\nchoroid and cancers of the ocular surface are ongoing. Aura's mission is to\nimprove outcomes for patients living with ocular cancers by delivering a\ntherapy that not only arrests tumor growth but also preserves vision and\nquality of life.\n\nFor more information, visit aurabiosciences.com\n(https://www.globenewswire.com/Tracker?data=QjwCmJi5polviKtuuL5SXXs8dXhuoPpT_Goa5vcHq3MAKDHVd-M9xj6nFMvZJwHdmJGKDtgMRJoqgrQUTKxlfiCM3rnQsfc1HDWC5YehvJo=).\nFollow us on X, @AuraBiosciences, and visit us on LinkedIn.\n\nInvestor and Media Relations Contact:\n\nAlex Dasalla\n\nHead of Investor Relations and Corporate Communications\n\nIR@aurabiosciences.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T20:01:00.225367092Z","server_sent_at_ms":1788379260225},"received_at":"2026-09-02T20:01:00.372Z","source_url":null},"analysis":{"id":"123207","press_release_id":"134313","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Aura Biosciences (NASDAQ: AURA) announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.\n\nHolles will take part in a fireside chat at 2:35 p.m. ET, with a live webcast available on the company's investor relations site and a replay archived for 90 days.\n\nAura is a clinical-stage biotechnology company developing bel-sar, a first-in-class therapy for ocular cancers, whose Phase 3 registration study in early choroidal melanoma is fully enrolled.\n\nThe release contains no new financial or clinical data and functions purely as an investor calendar notice.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference scheduling notice — note the September 16 fireside chat for anyone tracking bel-sar Phase 3 commentary, but no standalone post warranted."},"keyFigures":{},"namedEntities":{"people":[{"name":"Natalie Holles","role":"CEO and President"},{"name":"Alex Dasalla","role":"Head of Investor Relations and Corporate Communications"}],"products":["bel-sar"],"companies":[{"name":"Aura Biosciences, Inc.","ticker":"AURA","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations scheduling notice for a fireside chat at the Morgan Stanley Global Healthcare Conference. No new financial results, clinical data, or corporate developments are disclosed."},"tickerRelevance":{"others":[],"primary":"AURA"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-notice","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Aura Biosciences (NASDAQ: AURA) announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.\n\nHolles will take part in a fireside chat at 2:35 p.m. ET, with a live webcast available on the company's investor relations site and a replay archived for 90 days.\n\nAura is a clinical-stage biotechnology company developing bel-sar, a first-in-class therapy for ocular cancers, whose Phase 3 registration study in early choroidal melanoma is fully enrolled.\n\nThe release contains no new financial or clinical data and functions purely as an investor calendar notice.","key_figures":{},"named_entities":{"people":[{"name":"Natalie Holles","role":"CEO and President"},{"name":"Alex Dasalla","role":"Head of Investor Relations and Corporate Communications"}],"products":["bel-sar"],"companies":[{"name":"Aura Biosciences, Inc.","ticker":"AURA","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T20:02:33.300Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-notice","issuerAuthored":true,"newInformation":false}},"durationMs":44099,"modelName":"glm-4.7"}}